Come up with a name for your new list and we'll add to it:
Kyalin Biosciences was acquired by
Retrophin on December 12, 2013.
Kyalin Biosciences develops therapies targeting the core symptoms of autism and related conditions. Kyalin is currently developing a highly optimized intranasal delivery form of carbetocin, the latter…